Clinical course of pharyngotonsillitis with group A streptococcus treated with different penicillin V strategies, divided in groups of Centor Score 3 and 4: a prospective study in primary care.
Centor Score 3 and 4
Pharyngotonsillitis
Phenoxymethylpenicillin
Primary care
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
11 Nov 2022
11 Nov 2022
Historique:
received:
21
04
2022
accepted:
01
11
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
16
11
2022
Statut:
epublish
Résumé
Sore throat is a common reason for prescribing antibiotics in primary care, and 10 days of treatment is recommended for patients with pharyngotonsillitis with group A streptococcus (GAS). Our group recently showed that penicillin V (PcV) four times daily for 5 days was non-inferior in clinical outcome to PcV three times daily for 10 days. This study compares duration, intensity of symptoms, and side effects in patients with a Centor Score (CS) of 3 or 4 respectively, after treatment with PcV for 5 or 10 days and evaluates whether all patients with pharyngotonsillitis with a CS of 3 or 4 should be treated for 5 days or if severity of symptoms or CS suggest a longer treatment period. Data on symptoms and recovery from patient diaries from 433 patients included in a RCT comparing PcV 800 mg × 4 for 5 days or PcV 1 g × 3 for 10 days was used. Patients six years and older with CS-3 or CS-4 and positive rapid antigen detection test for GAS-infection were grouped based on CS and randomized treatment. Comparisons for categorical variables were made with Pearson's chi-squared test or Fisher's exact test. Continuous variables were compared with the Mann-Whitney U test. Patients with CS-3 as well as patients with CS-4 who received PcV 800 mg × 4 for 5 days self-reported that they recovered earlier compared to patients with CS-3 or CS-4 who received treatment with PcV 1 g × 3 for 10 days. In addition, the throat pain as single symptom was relieved 1 day earlier in patients with CS-4 and 5 days of treatment compared to patients with CS-4 and 10 days of treatment. No differences in side effects between the groups were found. Intense treatment with PcV four times a day for 5 days seems clinically beneficial and strengthens the suggestion that the 4-dose regimen with 800 mg PcV for 5 days may be the future treatment strategy for GAS positive pharyngotonsillitis irrespectively of CS-3 or CS-4. Trail registration ClinicalTrials.gov ID: NCT02712307 (3 April 2016).
Sections du résumé
BACKGROUND
BACKGROUND
Sore throat is a common reason for prescribing antibiotics in primary care, and 10 days of treatment is recommended for patients with pharyngotonsillitis with group A streptococcus (GAS). Our group recently showed that penicillin V (PcV) four times daily for 5 days was non-inferior in clinical outcome to PcV three times daily for 10 days. This study compares duration, intensity of symptoms, and side effects in patients with a Centor Score (CS) of 3 or 4 respectively, after treatment with PcV for 5 or 10 days and evaluates whether all patients with pharyngotonsillitis with a CS of 3 or 4 should be treated for 5 days or if severity of symptoms or CS suggest a longer treatment period.
METHOD
METHODS
Data on symptoms and recovery from patient diaries from 433 patients included in a RCT comparing PcV 800 mg × 4 for 5 days or PcV 1 g × 3 for 10 days was used. Patients six years and older with CS-3 or CS-4 and positive rapid antigen detection test for GAS-infection were grouped based on CS and randomized treatment. Comparisons for categorical variables were made with Pearson's chi-squared test or Fisher's exact test. Continuous variables were compared with the Mann-Whitney U test.
RESULTS
RESULTS
Patients with CS-3 as well as patients with CS-4 who received PcV 800 mg × 4 for 5 days self-reported that they recovered earlier compared to patients with CS-3 or CS-4 who received treatment with PcV 1 g × 3 for 10 days. In addition, the throat pain as single symptom was relieved 1 day earlier in patients with CS-4 and 5 days of treatment compared to patients with CS-4 and 10 days of treatment. No differences in side effects between the groups were found.
CONCLUSION
CONCLUSIONS
Intense treatment with PcV four times a day for 5 days seems clinically beneficial and strengthens the suggestion that the 4-dose regimen with 800 mg PcV for 5 days may be the future treatment strategy for GAS positive pharyngotonsillitis irrespectively of CS-3 or CS-4. Trail registration ClinicalTrials.gov ID: NCT02712307 (3 April 2016).
Identifiants
pubmed: 36368940
doi: 10.1186/s12879-022-07830-4
pii: 10.1186/s12879-022-07830-4
pmc: PMC9652839
doi:
Substances chimiques
Penicillin V
Z61I075U2W
Banques de données
ClinicalTrials.gov
['NCT02712307']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
840Subventions
Organisme : Futurum - Akademin för Hälsa och Vård, Region Jönköpings läns
ID : Futurum - 937705
Organisme : Folkhälsomyndigheten
ID : 05262-2020
Informations de copyright
© 2022. The Author(s).
Références
BMJ. 2019 Oct 4;367:l5337
pubmed: 31585944
BMJ. 2013 Oct 10;347:f5806
pubmed: 24114306
BMJ. 2003 Dec 6;327(7427):1324
pubmed: 14656841
Antibiotics (Basel). 2020 Oct 26;9(11):
pubmed: 33114471
Pediatr Infect Dis J. 2015 Jun;34(6):557-61
pubmed: 25973933
J Clin Microbiol. 1996 Apr;34(4):953-8
pubmed: 8815115
BMJ. 2000 Jan 15;320(7228):150-4
pubmed: 10634735
Br J Gen Pract. 2017 Sep;67(662):e623-e633
pubmed: 28808076
J Antimicrob Chemother. 2018 Oct 1;73(10):2883-2892
pubmed: 29955785
J Infect Dis. 2003 Nov 15;188(10):1578-86
pubmed: 14624385
J Clin Microbiol. 2009 Aug;47(8):2658-61
pubmed: 19515840
J Antimicrob Chemother. 2021 Jul 26;76(12 Suppl 2):ii7-ii13
pubmed: 34312654
Cochrane Database Syst Rev. 2012 Aug 15;(8):CD004872
pubmed: 22895944
Scand J Infect Dis. 1988;20(1):37-46
pubmed: 3129780
Lancet. 2005 Feb 12-18;365(9459):579-87
pubmed: 15708101
Clin Microbiol Infect. 2015 Mar;21(3):263.e1-7
pubmed: 25658556
Med Decis Making. 1981;1(3):239-46
pubmed: 6763125
Drug Resist Updat. 2011 Apr;14(2):107-17
pubmed: 21440486
J Infect. 2014 Jan;68(1):50-7
pubmed: 23999149
Diagn Microbiol Infect Dis. 2011 Feb;69(2):117-22
pubmed: 21251553
Cochrane Database Syst Rev. 2013 Nov 05;(11):CD000023
pubmed: 24190439
PLoS Negl Trop Dis. 2018 Mar 19;12(3):e0006335
pubmed: 29554121
Cochrane Database Syst Rev. 2021 Dec 9;12:CD000023
pubmed: 34881426
BMC Infect Dis. 2016 Nov 25;16(1):709
pubmed: 27887585
Am J Dis Child. 1987 Feb;141(2):224-7
pubmed: 3101484
Clin Microbiol Infect. 2012 Apr;18 Suppl 1:1-28
pubmed: 22432746